4AT Study
Start date:August 2015 End date:
Predicted June 2017 Co-ordinated by:
EMERGE team on behalf of University of Edinburgh and NHS Lothian Main trial site:
RIE
The 4AT as a triage test for delirium: a validation study in acutely hospitalised older patients.
Aim
To determine the diagnostic accuracy of the 4AT for delirium versus the reference standard of a DSM-IV diagnosis
Trial Design
Patients undergo a standard delirium assessment, and either the 4AT or the Confusion Assessment Method (CAM). Clinical outcomes and resource utilisation are recorded at 12 weeks after admission.
Eligibility criteria
Patients aged over 70 admitted to the Emergency Department.
Chief Investigator
Professor Alasdair MacLullich
Professor of Geriatric Medicine
Research Team
Allan MacRaild
Stroke Lead Research Nurse
Jill Steven
Senior Research Nurse - 4AT study
Mia Paderanga
Senior Research Nurse
Megan McGrath
Senior Research Nurse
Emma Ward
Research Administrator
Related news
4AT team attends British Geriatric Society conference
5 Nov 2015 | Allan MacRaild
Emerge sent two research nurses to the British Geriatric Society (BGS) conference. Jill Steven and Allan MacRaild are recruiting to a study entitled The 4AT as a triage test for delirium: a validation study in acutely hospitalised older patients. This study is a first collaboration between Emerge and Medicine of the Elderly with this study being led by Professor Alasdair MacLullich.
Read more
More EMERGE Trials
Assisting in identifying patients with Humeral shaft fractures in the ED by screening.
Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.
HU-FIX Trial
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.